DRL focused on securing supply chains

Amid growing concerns about potential US import tariffs on pharmaceuticals, Indian generics giant Dr. Reddy's Laboratories (DRL) is taking steps to secure its supply chain for key products entering the American market, chief executive Erez Israeli said.

- Jessica Jani

"The main concern is a potential disruption of supply...most of the activities that we are doing now is working closely with the customers and creating the relevant inventory, service, orders and everything that allows us to give good service," said Israeli, adding that "service is our number one priority". Israeli was speaking at a media briefing on Friday after the company posted its Q4 FY25 results.

Dr. Reddy's completed the divestment of its manufacturing facility in Shreveport, Louisiana, in the January-March quarter of FY25. This was unrelated to the tariffs, Israeli said. "The facility could not serve our needs in terms of products and activities unrelated to tariffs," he said.